The predictive models and all information available and presented on this webpage were developed for and are intended for research purposes only. The predictive models and all information available on this webpage must under no circumstances be used, wholly or partly, for any clinical decision making and in any other way than for research purposes. The predictive models and all information available and presented on this webpage are intended for use by health care professionals (researchers) only and should under no circumstances be used by any non-health care professional.
If you are a patient or a relative, we strongly advice against using the predictive models and all information available on and presented on this webpage. Instead you should consult your attending physician for prognostic information.
We, the authors of "Simplicity at the cost of predictive accuracy in diffuse large B-cell lymphoma: a critical assessment of the R-IPI, IPI, and NCCN-IPI" and the institutions we represent, are not liable in any form or way for any damages, direct or indirect, arising out of or in connection to the use of the predictive models or any information available on and presented on this webpage.
Patient characteristics
CLL-IPI
The predictive models and all information available and presented on this webpage were developed for and are intended for research purposes only. The predictive models and all information available on this webpage must under no circumstances be used, wholly or partly, for any clinical decision making and in any other way than for research purposes. The predictive models and all information available and presented on this webpage are intended for use by health care professionals (researchers) only and should under no circumstances be used by any non-health care professional.
If you are a patient or a relative, we strongly advice against using the predictive models and all information available on and presented on this webpage. Instead you should consult your attending physician for prognostic information.
We, the authors of "Simplicity at the cost of predictive accuracy in diffuse large B-cell lymphoma: a critical assessment of the R-IPI, IPI, and NCCN-IPI" and the institutions we represent, are not liable in any form or way for any damages, direct or indirect, arising out of or in connection to the use of the predictive models or any information available on and presented on this webpage.
Information
This web-page was developed at the department of Hematology, Aalborg University Hospital. The project was the result of extensive collaboration within the epidemiology working group of the Nordic Lymphoma group. The data was provided by the Danish Lymphoma Register (LYFO) and the Swedish Lymphoma Register (SLR).Contact
Forskningens Hus (Science and Innovation Center)
Aalborg University Hospital
Department of Haematology
Sdr. Skovvej 15
DK-9000 Aalborg
DENMARK
Telephone: +45 97 66 38 64
Fax: +45 97 66 63 23
E-mail: info@blodet.dk
Website: blodet.dk
Collaborators
Aalborg University Hospital
Jorne Biccler
Lasse Hjort Jakobsen
Martin Bøgsted
Tarec El-Galaly
Karolinska Intistutet
Sandra Eloranta
Karin Ekström Smedby
Lund University
Mats Jerkeman
Rigshopsitalet
Peter de Nully Brown
Michael Asger Andersen
Odense University Hospital
Henrik Frederiksen
References
Diffuse large B-cell lymphoma
Stacking model
Optimizing Outcome Prediction in Diffuse Large B-Cell Lymphoma by use of Machine Learning and Nationwide Lymphoma Registries: a Nordic Lymphoma Group Study
Jorne Biccler, Sandra Eloranta, Peter de Nully Brown, Henrik Frederiksen, Mats Jerkeman, Judit Jørgensen, Hans Erik Johnsen, Lasse Hjort Jakobsen, Karin E. Smedby, Martin Bøgsted, and Tarec C. El-Galaly
Submitted to Clinical Cancer Informatics
Cox proportional hazards model
Simplicity at the cost of predictive accuracy in diffuse large B-cell lymphoma: a critical assessment of the R-IPI, IPI, and NCCN-IPI
Jorne Biccler, Sandra Eloranta, Peter de Nully Brown, Henrik Frederiksen, Mats Jerkeman, Karin E. Smedby, Martin Bøgsted, Tarec C. El-Galaly
Published in Cancer Medicine, Vol. 7, Issue 1
IPI
A Predictive Model for Aggressive Non-Hodgkin's Lymphoma
The International Non-Hodgkin's Lymphoma Prognostic Factors Project
Published in New England Journal of Medicine 1993, Vol. 329, Issue 14
NCCN-IPI
An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era
Zheng Zhou, Laurie H. Sehn, Alfred W. Rademaker, Leo I. Gordon, Ann S. LaCasce, Allison Crosby-Thompson, Ann Vanderplas, Andrew D. Zelenetz, Gregory A. Abel, Maria A. Rodriguez, Auayporn Nademanee, Mark S. Kaminski, Myron S. Czuczman, Michael Millenson, Joyce Niland, Randy D. Gascoyne, Joseph M. Connors, Jonathan W. Friedberg and Jane N. Winter
Published in blood 2014, Vol. 123, Issue 6
R-IPI
The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP
Laurie H. Sehn, Brian Berry, Mukesh Chhanabhai, Catherine Fitzgerald, Karamjit Gill, Paul Hoskins, Richard Klasa, Kerry J. Savage, Tamara Shenkier, Judy Sutherland, Randy D. Gascoyne and Joseph M. Connors
Published in blood 2007, Vol. 109, Issue 5
Chronic lymphocytic leukemia
CLL-IPI
An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data
The International CLL-IPI working group
Published in The Lancet Oncology 2016, Vol. 109, Issue 5